BAM
KDNY

Belpointe Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Belpointe Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-107
Closed -$2.48K – 3664
2023
Q1 		$2.48K Buy
107
+24
+29% +$572 ﹤0.01% 3254
2022
Q4 		$2.17K Buy
+83
New +$1.84K ﹤0.01% 3229

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Belpointe Asset Management's KDNY Position: Q2 2023 in Review

Belpointe Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 107 shares — an estimated $2.48K sold.

Belpointe Asset Management first reported a position in KDNY in Q4 2022 and held it in 2 quarters. The position peaked at $2.48K in Q1 2023. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

  • Belpointe Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 107 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $2.48K.
  • Belpointe Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $2.48K in Q1 2023.
  • 185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.